TY - JOUR
T1 - Hematopoietic stem cell transplantation for chronic lymphocytic leukemia
AU - Gladstone, Douglas E.
AU - Fuchs, Ephraim
PY - 2012/3
Y1 - 2012/3
N2 - PURPOSE OF REVIEW: Although hematopoietic stem cell transplantation (HSCT) is the treatment of choice for many aggressive hematologic malignancies, the role of HSCT in chronic lymphocytic leukemia (CLL) has remained controversial. Now in the era of improved conventional treatment and better prognostication of long-term outcome, a review of autologous and allogeneic HSCT in CLL treatment is warranted. RECENT FINDINGS: Despite an improved disease-free survival in some patients, multiple, prospective, randomized autologous HSCT CLL trials fail to demonstrate an overall survival benefit as compared to conventional therapy. Allogeneic bone marrow transplantation, although limited by donor availability, can successfully eradicate CLL with adverse prognostic features. In the older CLL patients, nonmyeloablative allogeneic transplants are better tolerated than myeloablative transplants. Nonmyeloablative allogeneic transplants are less effective in heavily diseased burdened patients. SUMMARY: Outside of a clinical protocol, autologous HSCT for CLL cannot be justified. Nonmyeloablative allogeneic transplantation should be considered in high-risk populations early in the disease process, when disease burden is most easily controlled. Alternative donor selection using haploidentical donors and posttransplantation cyclophosphamide has the potential to vastly increase the availability of curative therapy in CLL while retaining a low treatment-related toxicity.
AB - PURPOSE OF REVIEW: Although hematopoietic stem cell transplantation (HSCT) is the treatment of choice for many aggressive hematologic malignancies, the role of HSCT in chronic lymphocytic leukemia (CLL) has remained controversial. Now in the era of improved conventional treatment and better prognostication of long-term outcome, a review of autologous and allogeneic HSCT in CLL treatment is warranted. RECENT FINDINGS: Despite an improved disease-free survival in some patients, multiple, prospective, randomized autologous HSCT CLL trials fail to demonstrate an overall survival benefit as compared to conventional therapy. Allogeneic bone marrow transplantation, although limited by donor availability, can successfully eradicate CLL with adverse prognostic features. In the older CLL patients, nonmyeloablative allogeneic transplants are better tolerated than myeloablative transplants. Nonmyeloablative allogeneic transplants are less effective in heavily diseased burdened patients. SUMMARY: Outside of a clinical protocol, autologous HSCT for CLL cannot be justified. Nonmyeloablative allogeneic transplantation should be considered in high-risk populations early in the disease process, when disease burden is most easily controlled. Alternative donor selection using haploidentical donors and posttransplantation cyclophosphamide has the potential to vastly increase the availability of curative therapy in CLL while retaining a low treatment-related toxicity.
KW - allogeneic
KW - autologous
KW - chronic lymphocytic leukemia
KW - hematopoietic stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=84857050271&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857050271&partnerID=8YFLogxK
U2 - 10.1097/CCO.0b013e32834f8011
DO - 10.1097/CCO.0b013e32834f8011
M3 - Review article
C2 - 22234253
AN - SCOPUS:84857050271
SN - 1040-8746
VL - 24
SP - 176
EP - 181
JO - Current opinion in oncology
JF - Current opinion in oncology
IS - 2
ER -